Hyperlipidemia Drugs Market To Reach $28.0 Billion By 2030

Hyperlipidemia Drugs Market Growth & Trends

The global hyperlipidemia drugs market size is expected to reach USD 28.0 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 2.8% from 2024 to 2030. Several factors, such as an increase in target population and growth in awareness about the risk of Cardiovascular Diseases (CVD) due to persistent hypercholesterolemia, are stoking the growth of the market.

Hyperlipidemia is the most common type of dyslipidemia and is generally caused by abnormally high lipid levels in the blood. This condition can occur due to genetic factors (primary hyperlipidemia) as well as other factors such as poor diet and unhealthy lifestyle (secondary hyperlipidemia). Statins are the first line of treatment for secondary hyperlipidemia.

The target population of antihyperlipidemic drugs is broadly divided into statin users and nonstatin users. The revenue share of statin users has been declining. The nonstatin users segment consists of a statin-intolerant and nonresponsive population as well as familial hyperlipidemia (FH) population. Nonstatin users are seeking high-efficacy alternatives and this is anticipated to boost the revenue of this segment.

Upcoming patent expirations are expected to lead to greater genericization in the market, mostly among statins, cholesterol absorption inhibitors, and combination drugs. However, new product launches are anticipated to continue to drive the market. Several novel mechanisms of action such as ACL inhibition, DGAT2 inhibition, and anti-ANGPTL-3 are being investigated for their potential for the treatment of hyperlipidemia as well as for reducing the risk of CVD.

 Request a free sample copy or view report summary: Hyperlipidemia Drugs Market Report

Hyperlipidemia Drugs Market Report Highlights

• Statins dominated the drug classes in 2023 owing to their high usage as the first line of therapy

• The recent launch of PCSK9 inhibitors, such as Repatha and Praluent, is likely to change the current therapeutic scenario due to their improved efficacy and safety profile

• PCSK9 inhibitors are expected to displace existing expensive therapies, lomitapide, and mipomersen for the treatment of homozygous FH patients

• There are fewer growth opportunities in Japan due to the unavailability of key pipeline drugs such as bempedoic acid

• North America held the largest market share of 39.4% in 2023 and Asia Pacific hyperlipidemia drugs market is expected to witness the fastest CAGR over the forecast period

Hyperlipidemia Drugs Market Segmentation

Grand View Research has segmented the global hyperlipidemia drugs market report based on drug class, route of administration, distribution channel, and region.

Hyperlipidemia Drugs Class Outlook (Revenue, USD Million, 2018 - 2030)

• Statins

• Bile Acid Sequestrants

• Cholesterol Absorption Inhibitors

• Fibric Acid Derivatives

• PCSK9 Inhibitors

• Combination

• Miscellaneous

Hyperlipidemia Drugs By Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Parenteral

• Others

Hyperlipidemia Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Online Pharmacies

• Retail Pharmacies

Hyperlipidemia Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • Kuwait

  • South Africa

List of Key Players in the Hyperlipidemia Drugs Market

• AstraZeneca

• Merck & Co., Inc.

• Pfizer Inc.

• Daiichi Sankyo Company Limited

• Amgen Inc.

• Sanofi

• Viatris Inc.

• Esperion Therapeutics, Inc.